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Abstract
Biochemical assessment of iron status relies on serum-based indicators, such as serum ferritin 
(SF), transferrin saturation, and soluble transferrin receptor (sTfR), as well as erythrocyte 
protoporphyrin (EP). These indicators present challenges for clinical practice and national 
nutrition surveys, and often iron status interpretation is based on the combination of several 
indicators. The diagnosis of iron deficiency (ID) through SF concentration, the most commonly 
used indicator, is complicated by concomitant inflammation. sTfR concentration is an indicator of 
functional ID that is not an acute-phase reactant, but challenges in its interpretation arise due to the 
lack of assay standardization, common reference ranges, and common cutpoints. It is unclear 
which indicators are best suited to assess excess iron status. The value of hepcidin, non-transferrin 
bound iron, and reticulocyte indices is being explored in research settings. Serum-based indicators 
are generally measured on fully-automated clinical analyzers available in most hospitals. Although 
international reference materials have been available for years, the standardization of 
immunoassays is complicated by the heterogeneity of antibodies used and the absence of physico-
chemical reference methods to establish “true” concentrations. From 1988 to 2006, the assessment 
of iron status in the National Health and Nutrition Examination Survey (NHANES) was based on 
the multi-indicator ferritin model. However, the model did not indicate the severity of ID and 
produced categorical estimates. More recently, iron status assessment in NHANES has used the 
total body iron stores (TBI) model, in which the log ratio of sTfR to SF is assessed. Together, sTfR 
and SF concentrations cover the full range of iron status. The TBI model better predicts the 
absence of bone marrow iron than SF concentratio alone and TBI can be analyzed as a continuous 
variable. Additional consideration of methodologies, interpretation of indicators, and analytical 
standardization is important for further improvements in iron status assessment.
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Introduction
Biochemical assessment of iron status relies mainly on serum-based indicators. The focus of 
indicators has largely been deficiency states, whereas questions of measuring iron repletion 
and iron overload have received less attention. Importantly, even though a panel of iron 
status indicators is routinely used in clinical practice and as part of national nutrition 
surveys, numerous challenges remain with the laboratory measurement and interpretation of 
these data.
This article provides an overview of commonly available indicators of iron status and their 
analytical challenges as well as discussions related to a ratio of two measures to determine 
status and newer indicators of iron status. Iron status assessment in NHANES is also 
reviewed. Currently, the Biomarkers of Nutrition for Development (BOND)5 project aims to 
provide evidence-based advice to researchers with an interest in the role of nutrition in 
health (1). Iron is one of six nutrients in the BOND project, and the iron expert panel has 
assembled comprehensive information on the current state of the art with regard to specific 
iron biology and available indicators for assessing iron status at the individual and 
population level. Upon completion, this work will be available in the peer-reviewed 
literature.
Commonly used iron status indicators and their analysis
Nature of commonly used indicators
Iron balance is a tightly controlled process that can be reflected in a number of iron status 
indicators. Its hallmark is rigorous regulation of absorption. There are three main body iron 
compartments that describe iron status inadequacy: iron stores, transport iron (iron to meet 
cellular requirements), and functional iron (iron available to tissues) (see Table 1). Depletion 
of each compartment leads to a different iron deficiency stage (2). Short-term variations in 
physiological iron needs are met by the release of iron stores, the majority of which are 
available as intracellular ferritin, predominantly in hepatocytes and specialized 
macrophages. The “gold standard” indicator that provides estimates of the size of the iron 
store is stainable bone marrow iron, but for obvious reasons it is not a practical 
measurement. Serum ferritin (SF) represents a small fraction of the body’s ferritin pool 
(Table 1), but the concentration of SF is reflective of the level of iron stores (3). Once iron 
stores are depleted, the first stage of iron deficiency (ID) is reached, namely iron depletion, 
but there are no erythropoietic consequences yet.
5Abbreviations used: ACD, anemia of chronic disease; BOND, Biomarkers of Nutrition for Development; EP, erythrocyte 
protoporphyrin; Hb, hemoglobin; ID, iron deficiency; IDA, iron deficiency anemia; NIST, National Institute of Standards and 
Technology; NTBI, non-transferrin bound iron; RBC, red blood cell; SF, serum ferritin; sTfR, soluble transferrin receptor; TBI, total 
body iron stores; TIBC, total iron-binding capacity; Tf, transferrin; TSAT, transferrin saturation; UIBC, unsaturated iron-binding 
capacity; ZPP, zinc protoporphyrin.
Pfeiffer and Looker Page 2
Am J Clin Nutr. Author manuscript; available in PMC 2018 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
The iron supply provided by the transport iron compartment is mainly for red blood cell 
(RBC) production because the demand for iron for erythropoiesis is much larger than that 
for other tissues. If the supply can no longer be met, the second stage of ID, namely iron-
deficient erythropoiesis, is reached without showing a notable decrease in hemoglobin (Hb) 
concentration. Indicators that provide information about the adequacy of iron supply are 
transferrin saturation (TSAT), and the concentrations of erythrocyte protoporphyrin (EP) and 
soluble transferrin receptors (sTfR) (4). TSAT represents the percentage of binding sites on 
all transferrin (Tf) molecules occupied with iron molecules (Figure 1) and is calculated as 
the ratio of serum iron to Tf or serum iron to total iron-binding capacity (TIBC). If 
unsaturated iron-binding capacity (UIBC) is measured, TIBC is calculated as the sum of 
serum iron and UIBC. The measured plasma or serum pool of iron is the fraction of iron that 
circulates bound primarily to Tf. The so called non-transferrin bound iron (NTBI), iron 
bound to low molecular weight proteins or other compounds, usually comprises less than 1% 
of the total plasma iron pool and is usually not detected in most routine assays (4). EP is a 
generic term for either the directly measured concentration of zinc protoporphyrin (ZPP), the 
form present in erythrocytes, or the free EP concentration measured after extraction. 
Although ZPP is often referred to as an indicator of iron status, for the purposes of this 
manuscript EP is used mainly because NHANES did not measure ZPP, but instead measured 
free EP. sTfR is a truncated fragment of the transferrin receptor 1 and it circulates in plasma 
bound to Tf.
Hb concentration is the key indicator for a functionally important iron deficit, specifically 
iron deficiency anemia (IDA) (Table 1) (5). The hematocrit or packed cell volume provides 
no additional information beyond Hb. IDA is one of several nutritional anemias; depleted 
folate or vitamin B12 stores can also cause anemia and low Hb concentrations. Non-iron 
related anemia can also be caused by blood loss, decreased or faulty RBC production, or 
destruction of RBCs.
Consideration of the common indicators requires that the biological confounding caused by 
inflammation be taken into account. Inflammation, a highly complex biological process (6), 
confounds interpretation of iron status indicators, especially of SF concentration because it 
increases in response to inflammation as well as to increased iron stores (Table 2). 
Discussions are ongoing regarding how to account for the amount of inflammation when 
interpreting iron status in a population (6).
In uncomplicated IDA (no inflammatory response), iron stores, transport iron, and functional 
iron (e.g., iron available to tissues) are all reduced (Table 3). As soon as iron supply to 
erythropoiesis becomes insufficient, transferrin production is upregulated to increase iron 
transport, transferrin receptor production is upregulated to facilitate iron delivery to cells 
resulting in an increase in serum sTfR, and ZPP is produced instead of heme resulting in an 
increase in EP. SF and Hb concentrations are important indicators in uncomplicated IDA.
In anemia of chronic disease (ACD), the inflammatory response is increased, which causes 
iron stores to be sequestered (7). SF, being an acute-phase protein, appears normal to 
increased even though functional iron is reduced. Transport iron shows a mixed response 
with reduced serum iron and Tf, increased EP, and normal sTfR concentration. When a 
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combination of IDA and ACD exists, the inflammatory response is increased, iron stores are 
reduced to normal, and functional iron is reduced. Transport iron indicators show reduced 
serum iron and Tf, normal to increased sTfR concentration, and increased EP. When 
inflammation complicates the interpretation of iron status, it is helpful to have data on 
several indicators.
The same iron status indicators mentioned above are used to determine iron adequacy or 
repletion, but concentrations of the indicators are neither reflective of ID nor of iron 
overload. In iron overload, SF and iron stores are increased and functional iron is normal. 
Transport iron indicators show increased serum iron, reduced Tf and EP, and normal sTfR. 
High SF concentration has a high sensitivity but low specificity to diagnose iron overload in 
hemochromatosis (8–10). The high within-person variability of TSAT limits its usefulness as 
an initial screening test for hemochromatosis (11), however elevated TSAT identifies 
patients at risk for organ iron overload that are eligible for further testing. EP has been 
shown to be of utility in distinguishing hemochromatosis from other conditions that lead to 
elevated SF as a result of ACD (12).
Finally, several other confounding factors should be noted for these status indicators (Table 
2). Although sTfR and EP are more specific indicators of iron deficiency erythropoiesis, 
both are also elevated in increased erythropoietic activity, and EP is also elevated in lead 
poisoning. Hb is decreased in pregnancy due to hemodilution and increased in heavy 
smokers, people who live at high altitudes, and in a state of dehydration. The within-person 
biologic variability for serum iron (~30%) is much higher than for SF (~10–25%) or even 
sTfR (~10%) (13–16), necessitating the analysis of more than one sample for clinical 
evaluation. However, this is typically not done in population surveys. Also, because of the 
relatively high diurnal variability of serum iron (but without a consistent pattern) (14, 17), 
collection of a specimen from fasting persons was recommended in the clinical setting, but 
was recently shown not to have an advantage over random sampling (11).
Analytical considerations
Preanalytical conditions—For serum-based iron status indicators, the preanalytical 
conditions required to obtain a valid sample for laboratory analysis are fairly easy to achieve 
(Supplemental Table 1). Whole blood needs to be refrigerated and processed the same day 
(iron) or within a few days (SF and sTfR) after blood collection to obtain serum(18, 19); 
serum is stable for at least a week at 4°C and at least a year at ≤−20°C(20–22); and the 
sample can be subjected to up to 3 freeze-thawing cycles without negatively affecting the 
biomarker concentrations (20). For optimal long-term storage, serum should be stored at ≤
−40°C. Data from our laboratory show that serum iron, SF, and sTfR were stable for at least 
10 y when stored at −70°C. While the preference for a particular anticoagulant in plasma 
and the influence of hemolysis and other preanalytical factors (e.g., bilirubin, lipemia) on the 
test result may be test specific, serum is usually the preferred matrix over plasma and iron 
measurement is generally more affected by hemolysis than SF and sTfR. For whole blood-
based iron status indicators, fresh whole blood needs to be analyzed directly for Hb or 
refrigerated for 1–2 d prior to analysis (23) and refrigerated whole blood is stable for a week 
if protected from UV light for analysis of EP (4).
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Laboratory methods—The measurement of hematologic indicators in general and Hb in 
particular is widely available in clinical and research laboratories by flow cytometry on 
fully-automated cell counters. These instruments can count different blood cells with good 
precision and high sample throughput. Battery-operated, hand-held hemoglobinometers can 
provide on-the-spot results from a single drop of blood collected in the field. However, these 
instruments require freshly collected blood and if capillary blood is used, proper sampling 
technique is critical to obtaining a valid specimen.
The measurement of serum-based biochemical indicators is generally carried out on fully-
automated clinical analyzers available in many laboratories. Protein-based indicators such as 
SF, Tf, and sTfR, are measured by immunoassays, whereas serum iron, TIBC, and UIBC are 
measured on chemistry analyzers using a colorimetric reaction with ferrine or ferrozine as a 
chromogen to form a color complex with iron. Most clinical analyzers measure UIBC 
because it is more easily automated than TIBC. The measurement precision of UIBC is good 
at high concentrations as found in iron depletion, but worse at low concentrations in the 
presence of iron overload (24). Outside the United States, testing for UIBC and TIBC has 
mostly been replaced by Tf. The precision of other biochemical indicators is good, with 
between-run CVs generally ≤5%.
Using clinical analyzers offers advantages, such as high sample throughput and quick 
turnaround time with minimum operator involvement, the availability of commercial kits for 
various instrument platforms, relatively low reagent cost (with the exception of sTfR), and 
generally good precision. Possibly the biggest caution for using commercial kits on clinical 
analyzers is that the user has no control over reagent lot-to-lot variation and assay 
reformulations. This is especially critical when the assay is employed in longitudinal studies 
such as national nutrition surveys, because small assay shifts could be misinterpreted as 
changes in population status. Another disadvantage of clinical analyzers is that the required 
sample volume is typically ≥150 μL, which may be problematic for pediatric or capillary 
samples. Lastly, clinical analyzers are moderately expensive and require regular maintenance 
and periodic technical service. Other less common analytical techniques to measure iron 
status indicators are summarized in Supplemental Table 2.
Standardization of iron status indicators—International reference materials are 
available for most iron status indicators from the National Institute of Standards and 
Technology (NIST) (for iron in form of an iron wire [SRM 937] or an iron standard solution 
[SRM 3126A]), the WHO through the United Kingdom National Institute of Biological 
Standards and Control (for Hb [IS 98/708], SF [RM 94/572], and sTfR [RR 07/202]), or the 
European Institute for Reference Materials and Measurements (for Tf [ERM-DA470]). The 
NIST reference materials provide certified values assigned by the use of high-order 
reference methods. However, physico-chemical reference methods are not available for the 
protein-based iron status indicators to establish “true” concentrations, thus value assignment 
has been done through consensus after analysis by common clinical assays (SF, Tf) or after 
determining the protein content in the reference material (sTfR). As a result, moderate (SF, 
Tf) to large (sTfR) assay differences, as discussed above, can be observed in proficiency 
testing programs and have been documented in other studies (25, 26). The difficulties in 
standardizing immunoassays have been reviewed (27) and include the heterogeneity of the 
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antibodies used resulting in different epitope specificities, technical difficulties in producing 
a reference material that is identical to the circulating serum form, and difficulties in 
measuring intact proteins by mass spectrometry, including the absence of stable-isotopically 
labeled proteins that can be used as internal standards.
Ratio of sTfR to SF as indicator of iron status
The ratio of sTfR to SF deserves separate discussion. This indicator is currently reported as 
part of the NHANES, but is less well known. There are several ways to express the ratio, and 
confusion exists as to how it is calculated, what it means, and what laboratory data can be 
used to calculate and interpret the ratio (Table 4). SF is a sensitive indicator until body iron 
stores (mainly in hepatocytes) are depleted, but concentrations below 12 μg/L are not 
indicative of the severity of the ID. On the other hand, serum sTfR is a sensitive indicator 
after body iron stores are depleted and concentrations keep increasing with increasing ID. 
Together, these 2 indicators assess the full range of iron status from severe deficiency to 
overload.
The logarithm of the ratio of sTfR to SF concentrations is linearly related to total body iron 
stores (TBI) expressed as mg/kg body weight, as shown in a unique phlebotomy study 
conducted in 14 healthy adult Caucasians (28). The sTfR assay used in that study was an in-
house ELISA assay (29), shown to perform equivalently to the Ramco sTfR assay (30). The 
Ramco assay was shown to measure approximately 50% higher than the Roche sTfR assay 
(30).
TBI is one of several terms found in the literature for this indicator; body iron is the original 
term used by the investigators who developed this methodology (28), but some reports also 
used body iron stores or total body iron. Regardless of the term used, it is important to 
understand that TBI is not a measure of the quantity of iron in the individual’s body. It 
merely provides a quantitative estimate of the size of the body iron store when iron is 
present in the store (values >0 mg/kg) or the size of the functional deficit that would need to 
be corrected before iron could again be accumulated in the store in an individual who is iron 
deficient (values ≤0 mg/kg). It is expressed as a continuous variable that is conceptually easy 
to interpret and indicates the severity of the iron deficit at the low end of the spectrum and 
the magnitude of the iron surplus at the high end of the spectrum. Some investigators have 
proposed that the term “body iron index” might be more appropriate. The formula for this 
relationship was validated using data from 3 published studies (31): a non-representative 
subset of healthy adult Caucasians participating in NHANES III (1988–1994) (31, 32), 
pregnant Jamaican women participating in an iron supplementation trial (33), and anemic 
Vietnamese women participating in an intervention trial with iron-fortified fish sauce (34). 
The same shortcoming of assay dependency as described above for the simple ratio also 
applies to the TBI indicator. TBI has been used in a study that employed an in-house 
multiplex ELISA sTfR assay believed to be equivalent to the Ramco assay (35) and in 
several NHANES data analyses that employed the Roche sTfR assay (36–38).
Alternatively, the utility of the simple ratio of sTfR to SF concentrations (both expressed in 
μg/L) was confirmed in an iron supplementation trial in pregnant women in Jamaica, where 
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the ratio of the supplemented group was significantly different from that in the 
nonsupplemented group (mean values of 470 vs. 1200, respectively) (33). However, because 
of large differences in sTfR assays, the cutpoint for the simple ratio (≤500 ample iron stores, 
>500 depleted iron stores) is assay dependent and can only be used with data generated by 
an assay that performs equivalently to the Ramco or Roche assay. The simple ratio has been 
used by several investigators who employed the Ramco sTfR assay (39–41) or an assay 
believed to be equivalent to the Ramco assay (42).
Finally, the sTfR index, calculated as the ratio of sTfR to the logarithm of SF, was 
introduced as an indicator to identify persons with depleted iron stores (43) and cutpoint 
values (mg/L) were published to distinguish between ACD (<1) and IDA (>2) or both 
conditions (>2) (7). The sTfR index was adopted on the Access Beckman Coulter analyzer 
for differential diagnosis of IDA and ACD (44). The interpretation of the sTfR index is also 
assay dependent. One study that employed the Roche sTfR assay (45) calculated the sTfR 
index, which is not appropriate because the Roche assay does not produce comparable 
results to the Beckman sTfR assay.
Emerging iron status indicators
Hepcidin, NTBI, and reticulocyte indices are currently viewed as experimental indicators 
used mainly in the research setting. Hepcidin, the central regulator of iron homeostasis, 
increases with increasing iron status(46, 47). Hepcidin may be clinically useful in the 
diagnosis of some types of anemia, in the differentiation between IDA and ACD, and in 
patients with iron overload syndromes (48, 49). Because hepcidin is an important 
determinant of dietary iron absorption, it may guide safe iron supplementation in countries 
with high infection burden (46). Its role in determining whether iron status is replete is 
unclear. Hepcidin is an acute-phase reactant (50), is suppressed in the presence of increased 
erythropoietic activity unrelated to iron status (51), and has a large (49%) intra-individual 
variability (52). Hepcidin can be measured with good reproducibility in serum or urine by 
mass-spectrometry assays or immunoassays, but there are considerable assay differences and 
no standardization yet (53). A recent inter-laboratory comparison study identified a 
commutable secondary reference material, which–if used as a common calibrator–could 
harmonize assay results to an achievable equivalence of 7.7% from the current 28.6% (53).
NTBI has a postulated role in the pathogenesis of iron toxicity due to oxidative damage and 
the risk for increased susceptibility to infectious diseases such as malaria (54). NTBI 
appears in the circulation of patients with iron overload or for a short time after the 
administration of an iron dose and may thus be of interest to distinguish between iron 
repletion and iron excess. The fraction of plasma NTBI that is redox active and can be 
chelated is designated labile plasma iron (LPI) (55). The measurement of serum NTBI is 
fraught with technical difficulties related to the determination of heterogeneous chemical 
forms of circulating NTBI, as demonstrated in an international round robin by considerable 
method differences (40-fold variation) and large analytical variation (4.4–193%) (56). A 
second international round robin of current leading analytical assays for NTBI and LPI 
indicated good assay reproducibility, but still relatively poor correlation and agreement 
among assays (57). Recently, a new NTBI assay system utilizing a conventional automated 
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analyzer was reported to have good linearity, reproducibility, and comparability with HPLC 
(58).
Reticulocyte indices are sensitive indicators for iron-deficient erythropoiesis(59). For 
example, reticulocyte hemoglobin content is useful in assessing the functional iron available 
for erythropoiesis during the previous 3–4 days, while reticulocyte volume is a useful 
indicator when monitoring the therapeutic response of anemias. Automated flow-cytometric 
analysis provides acceptable precision and bias, yet method-specific reference intervals have 
to be currently used (59). Standardization of these measurements is encouraged. 
Preanalytical variation (related to specimen transportation and storage) represents the major 
source of inaccurate test results. The high sample related uncertainty requires that 
reticulocytes be analyzed without delay. Reticulocyte indices have been included in the 
American Academy of Pediatrics guidelines for the evaluation of childhood anemia (60) and 
have been used in patients with chronic kidney disease to manage iron status and predict the 
responsiveness to intravenous iron and erythropoiesis stimulating agents (61).
Iron status assessment in NHANES
Monitoring the iron status of the U.S. population has been an important component of the 
NHANES since its inception in 1971. All NHANES surveys have included a battery of 
hematologic and biochemical indicators in order to provide the best possible assessment 
(Supplemental Table 3) (62, 63). A matrix describing the laboratory methods by indicator 
and survey cycle is shown in Supplemental Table 4. Details for each method can be found on 
the NHANES website (64).
Three models that employed multiple iron status indicators were developed by an expert 
committee to assess the iron status of the U.S. population using data from NHANES II 
(1976–1980) (65). One of these models, called the ferritin model, has been used with data 
from several subsequent NHANES surveys conducted between 1988–2006 (32, 66, 67). The 
other 2 models (known as the MCV model and Hb shift model) have been discussed 
elsewhere (65). The ferritin model uses SF, TSAT and EP. To meet the definition of ID using 
the ferritin model, an individual had to have abnormal values for two or more indicators. 
Because the model included SF, it was believed more likely to capture the early stages of ID, 
including iron depletion (65).
Cutpoints to define abnormal values for the indicators used in the ferritin model were 
validated in clinically-diagnosed patients whenever possible. This type of data was not 
available for children and adolescents, so cutpoints for these age groups were selected by 
identifying a value that kept the percentage of falsely identified individuals similar to that of 
women ages 20–44 y. Several types of studies provided data to validate the ferritin model for 
defining ID: a) comparison of anemia rates among individuals with abnormal values for <2 
vs. ≥2 indicators used in the ferritin model(65, 68–70); b) assessment of whether the 
prevalence of ID (as defined by the ferritin model) followed expected patterns by selected 
demographic characteristics (65); c) examination of whether the prevalence of ID by the 
ferritin model changed in response to oral iron treatment (71); d) comparison of ferritin 
model prevalence with prevalence of iron depletion by estimated stores or bone marrow 
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staining (72, 73); and e) examination of whether including additional indicators in a 
regression model increased the predictive ability of the model above that observed for SF 
concentrations alone (74). One issue that complicates the interpretation of the preceding 
bone marrow studies is the use of different endpoints that may address slightly different 
stages in the development of ID. In specific, the ferritin model may assess a slightly later 
stage of ID than presence/absence of bone marrow iron stores (model includes TSAT and EP 
and thus detects iron-deficient erythropoiesis in addition to iron store depletion) and may 
therefore be expected to produce a lower prevalence. This is supported by findings from 
Cook et al. (72) that noted similar prevalences between the ferritin model and estimated 
body iron stores of −100 mg/kg.
In the early 2000s interest grew to consider a simpler approach to define iron status in 
NHANES. Assays for some of the indicators used in the ferritin model were labor intensive 
and no longer widely used, and it was becoming increasingly difficult to find laboratories 
that were willing to continue performing them. A simpler approach involving fewer iron 
status indicators may also reduce survey complexity and cost. Around that time, the 
validation of the TBI model was published (31), a WHO recommendation suggesting the use 
of SF and sTfR to assess the iron status of populations became available (75), and the fully-
automated Roche sTfR assay that provided higher sample throughput and better precision 
than the Ramco sTfR assay was released (30). In 2005, CDC convened a workshop with 
experts in iron metabolism to discuss whether the ferritin model could be replaced with the 
TBI model starting with NHANES 2003–2004 and what the most appropriate approach to 
assess iron status in pregnant women would be. The advantages of using a simpler model 
had to be weighed against the possible effect on the ability to assess changes in iron status 
over time if the ferritin model was replaced. An important aspect of assessing iron status of 
populations is to ensure coverage of all high-risk groups. Prior to 2003, iron status indicators 
were measured in the entire population. From 2003 on, NHANES concentrated on assessing 
iron status in children ages 1–5 y and women of reproductive age (12–49 y). Pregnant 
women were oversampled during NHANES 1999–2006, which provided a sufficient sample 
size to calculate baseline estimates for an objective on ID in pregnant women for Healthy 
People 2010, the nation’s prevention agenda (76).
One of the strengths of the TBI model was the derivation from the direct calculation of body 
iron stores from serial phlebotomy (25), a “gold standard” method for assessment of TBI. 
Like the ferritin model, the TBI model has also been indirectly validated by: a) assessment 
of whether the prevalence of ID as estimated by the model followed expected patterns by 
selected demographic characteristics, such as age and sex (31, 72, 77); b) examination of the 
changes in body iron stores and the prevalence of low body iron stores in response to oral 
iron treatment (31); and c) comparison of SF, sTfR or the ratio of the two with absent 
stainable bone marrow iron in anemic patients (43, 78). Although the third group of studies 
provided some information, it cannot be seen as a direct validation because all of the patients 
were anemic and the indicators (SF and sTfR) were not combined in the same mathematical 
manner and may represent a different construct.
There was limited evidence that the TBI model may be valid for pregnant women: the 
pattern of body iron stores in pregnant Jamaican and Bolivian women followed expected 
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patterns (33, 77); unpublished data for US women in the third trimester of pregnancy 
presented at the workshop also supported its utility for this group.
The expert panel proposed that the ferritin model be replaced with the TBI model for 
assessing iron status in the population, including pregnant women. In order to permit secular 
trend analyses for Healthy People 2010, a gradual switch to the new model, with an overlap 
period during which both models can be applied (2003–2006), was recommended. The panel 
recommended that trimester-specific estimates be provided for pregnant women, regardless 
of which method was used to define their iron status. Table 5 provides advantages and 
disadvantages for these 2 models as well as a list of selected NHANES publications that 
used these 2 models.
Summary and research needs for iron status indicators
The laboratory assessment of iron status relies on a combination of biochemical indicators. 
Although it has been pointed out that there is a need to link these iron indicators better to 
meaningful clinical outcomes (79), such efforts must be underpinned by a sound 
understanding of the indicators available. Diagnosis of ID through SF concentration is 
complicated by concomitant inflammation, as is the case with ACD. Lack of assay 
standardization for sTfR, an indicator of functional ID less affected by inflammation, results 
in a lack of common reference ranges and cutpoints. It is unclear which indicators are best 
suited to assess adequate or excess iron status. Whereas laboratory methods for commonly 
used iron indicators are widely available and provide good precision, the comparability of 
results across assay platforms could be further improved for SF and require harmonization 
for sTfR to become a more widely used indicator. High-order reference methods and 
certified reference materials are needed for iron status indicators. At the same time, the 
availability of simple yet reliable assays that can multiplex the measurement of several 
indicators using minimal specimen volume would be beneficial for pediatric and capillary 
samples. The utility of newer iron status indicators, such as hepcidin and NTBI, is being 
explored mainly in the research setting, but laboratory methods for these indicators require 
further improvements in terms of comparability and for NTBI also in terms of the definition 
of the clinically most relevant forms of NTBI.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Laboratory measurement of iron indicators needed to calculate transferrin saturation. TIBC, 
total iron-binding capacity; UIBC, unsaturated iron-binding capacity.
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